Switch Therapeutics
Kevin Zhang is a Partner at Upfront Ventures, where involvement includes supporting early-stage investments in various technology sectors, particularly healthcare and fintech, since October 2012. Prior to this role, Kevin held positions as Principal, Senior Associate, and Associate at the same firm. In addition to ongoing work at Upfront Ventures, Kevin serves as Seed Lead and Board Member for multiple companies, including CertifyOS, Omni Creator Products, Pragma Platform, Switch Therapeutics, Path, Stray Bombay Company, Reveleer, Tellie, and Canvas Medical. Kevin Zhang obtained an AB in Biology with a minor in Psychology from Harvard University between 2005 and 2009.
This person is not in any teams
This person is not in any offices
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.